title: Protease inhibitors: Part 4. Synthesis of weakly basic thrombin inhibitors incorporating pyridinium-sulfanilylaminoguanidine moieties.
abstract: Three series of derivatives have been prepared by reaction of sulfanilylaminoguanidine with pyrylium salts, with the pyridinium derivatives of glycine and with the pyridinium derivatives of beta-alanine, respectively. The new compounds were assayed as inhibitors of two serine proteases, thrombin and trypsin. The study showed that in contrast to the leads, possessing KI's around 100-300 nM against thrombin, and 450-1420 nM against trypsin, respectively, the new derivatives showed inhibition constants in the range of 15-50 nM against thrombin, whereas their affinity for trypsin remained relatively low. Derivatives of beta-alanine were more active than the corresponding glycine derivatives, which in turn were more inhibitory than the pyridinium derivatives of sulfanilylaminoguanidine possessing the same substitution pattern at the pyridinium ring. Thus, the present study proposes two novel approaches for the preparation of high affinity, specific thrombin inhibitors: a novel S1 anchoring moiety in the already large family of arginine/amidine-based inhibitors, i.e., the SO2NHNHC(=NH)NH2 group, and novel non-peptidomimetic scaffolds obtained by incorporating alkyl-/aryl-substituted-pyridinium moieties in the hydrophobic binding site(s). The first one is important for obtaining bioavailable thrombin inhibitors, devoid of the high basicity of the commonly used arginine/amidine-based inhibitors, whereas the second one may lead to improved water solubility of such compounds.
authors.affiliation: Università degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, Italy. cts@bio.chim.unifi.it
authors.forename: C T
authors.initials: CT
authors.lastname: Supuran
authors.forename: F
authors.initials: F
authors.lastname: Briganti
authors.forename: A
authors.initials: A
authors.lastname: Scozzafava
authors.forename: M A
authors.initials: MA
authors.lastname: Ilies
mesh_terms: D015195:Drug Design; D005998:Glycine / Q000737:chemistry; D019791:Guanidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D015394:Molecular Structure; D011726:Pyridinium Compounds / Q000494:pharmacology*; D015842:Serine Proteinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013450:Sulfones / Q000494:pharmacology*; D013917:Thrombin / Q000037:antagonists & inhibitors*; D014361:Trypsin Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D015091:beta-Alanine / Q000737:chemistry
chemical_list: D011726:Pyridinium Compounds; D015842:Serine Proteinase Inhibitors; D013450:Sulfones; D014361:Trypsin Inhibitors; D015091:beta-Alanine; D013917:Thrombin; D019791:Guanidine; D005998:Glycine